Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : Gets Funds From Bill & Melinda Gates Foundation to Treat Cryptosporidiosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2018 | 07:50am CEST
   By Marc Bisbal Arias 
 

Novartis AG (NOVN.EB) said Wednesday that it has signed an alliance with the Bill & Melinda Gates Foundation for further development of a drug that treats the diarrheal disease cryptosporidiosis.

The Swiss company said that the Gates Foundation will provide $6.5 million to support the development of Novartis's drug candidate KDU731.

"Cryptosporidiosis is the second leading cause of infectious diarrhea in children under two years of age," Novartis said. Diarrheal diseases cause around 525,000 deaths a year.

Write to Marc Bisbal Arias at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10:40aNOVARTIS : European Commission approves Sandoz`s Zessly to treat gastroenterolog..
AQ
09:50aGLOBAL ACTIVE PHARMACEUTICAL INGREDI : Pfizer, Inc., Novartis International AG, ..
AQ
05/25NOVARTIS : Patent Issued for Surgical Guidance and Planning Software for Astigma..
AQ
05/25NOVARTIS : Patent Issued for Ophthalmic Illumination Systems, Devices, and Metho..
AQ
05/25NOVARTIS : Patent Issued for Ophthalmic Lens Having an Extended Depth of Focus (..
AQ
05/25NOVARTIS : announces FDA approval of Gilenya® as the first disease-modifying the..
AQ
05/25FINDINGS IN THE AREA OF ONCOLOGY REP : a platform of basket trials)
AQ
05/25NOVARTIS` : Sandoz scores EU approval for Remicade biosimilar
AQ
05/25NOVARTIS : Sandoz receives European Commission approval for Zessly in gastroente..
AQ
05/25JOHNSON & JOHNSON : EU nod for Sandoz Remicade biosimilar Zessly
AQ
More news
News from SeekingAlpha
05/25ROUNDS REPORT : CryoPort Rallied While The FDA Approved Palynziq 
05/25Magenta Therapeutics on deck for IPO 
05/25Premarket analyst action - healthcare 
05/24'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisou.. 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
Financials ($)
Sales 2018 52 599 M
EBIT 2018 13 274 M
Net income 2018 9 218 M
Debt 2018 13 550 M
Yield 2018 3,89%
P/E ratio 2018 15,81
P/E ratio 2019 18,75
EV / Sales 2018 3,95x
EV / Sales 2019 3,80x
Capitalization 194 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 90,6 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-8.30%194 397
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970
AMGEN2.33%117 942